Web Content Display
Breadcrumb
Web Content Display
Web Content Display
Web Content Display
Web Content Display
Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer’s Disease Therapy - the qLIFE PRA
Advances in medical science and social development have resulted in a significant increase in human life expectancy. Unfortunately, there is a significant increase in the incidence of neurodegenerative diseases as well. Among them is also Alzheimer's disease, a chronic progressive and irreversible neurological disorder occurring in the central nervous system, the most common cause of dementia, accounting for 50% of dementia over the age of 65.
Despite the great efforts of researchers, there is still a lack of effective drugs suitable for the treatment of Alzheimer's disease (AD). On the initiative of the editor of a special issue of the journal "Molecules", who issued an invitation to write an article on this subject to Dr. hab. Agnieszka Zagórska, we now have the opportunity to read her publication entitled: "Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy”.
The article presents an overview of the biochemical mechanisms of AD development along with the prospects for the implementation of drugs effective in AD therapy. In the introduction, the main molecular targets for drugs* are discussed, together with a summary of their connection to the disease.
The aim of the article was to discuss a new approach to designing drugs effective in the treatment of AD based on the so-called multifunctional ligands. The article also highlights the latest publications referencing the enlarged panel of new biological targets for AD related to microglia.
* (starting from acetylcholine esterase (AChE) and beta-secretase 1, also known as beta 1 amyloid precursor protein cleavage enzyme (BACE-1) by beta glycogen synthetase kinase 3 (GSK-3), receptors for N-methyl- d-aspartate (NMDA), serotonin (5-HT), histamine (H3 receptor), phosphodiesterases (PDE) and monoamine oxidase (MAO)).
Publication available at:
https://www.mdpi.com/1420-3049/25/15/3337
The publication has been funded from the budget of the qLife Priority Research Area under the Strategic Programme Excellence Initiative at the Jagiellonian University.
The article on the qLIFE PRA website:
https://qlife.cm-uj.krakow.pl/aktualnosci/lekichorobaalzheimera/
Recommended
